{
  "thread": {
    "uuid": "eb5529b237d27f94ff0be8f8a0858057fe338c8d",
    "url": "https://www.flintrehab.com/can-semaglutide-or-tirzepatide-lower-stroke-risk/",
    "site_full": "www.flintrehab.com",
    "site": "flintrehab.com",
    "site_section": "https://www.flintrehab.com/rss",
    "site_categories": [
      "health",
      "physical_therapy",
      "heart_disease"
    ],
    "section_title": "Flint Rehab",
    "site_title": "Neuro Rehab &amp; Stroke Recovery Tools that Work | Flint Rehab",
    "title": "Can Semaglutide (Ozempic, Wegovy) or Tirzepatide (Mounjaro, Zepbound) Lower Stroke Risk?",
    "title_full": "Can Semaglutide (Ozempic, Wegovy) or Tirzepatide (Mounjaro, Zepbound) Lower Stroke Risk?",
    "published": "2025-07-23T23:32:00.000+03:00",
    "replies_count": 0,
    "participants_count": 1,
    "site_type": "news",
    "country": "US",
    "main_image": "https://flintrehab-cdn.s3.us-east-2.amazonaws.com/uploads/2025/07/23132859/can-semaglutide-or-tirzepatide-lower-stroke-risk.webp",
    "performance_score": 0,
    "domain_rank": 107135,
    "domain_rank_updated": "2025-06-03T00:00:00.000+03:00",
    "licensing_agency": [],
    "social": {
      "facebook": {
        "likes": 0,
        "comments": 0,
        "shares": 0
      },
      "vk": {
        "shares": 0
      }
    }
  },
  "uuid": "eb5529b237d27f94ff0be8f8a0858057fe338c8d",
  "url": "https://www.flintrehab.com/can-semaglutide-or-tirzepatide-lower-stroke-risk/",
  "ord_in_thread": 0,
  "author": "Elizabeth Denslow, OTR/L",
  "published": "2025-07-23T23:32:00.000+03:00",
  "title": "Can Semaglutide (Ozempic, Wegovy) or Tirzepatide (Mounjaro, Zepbound) Lower Stroke Risk?",
  "text": "For stroke survivors, the road to recovery can feel uncertain—especially when living with other health challenges like type 2 diabetes and obesity. But new research offers hope: two widely used diabetes medications, semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), may do more than just manage blood sugar. They could also help protect the brain and reduce your risk of future strokes.\nThe Connection Between Stroke, Diabetes, and Obesity\nIf you’ve had a stroke and also live with diabetes or obesity, you’re not alone—and you’re not without risk. These conditions increase inflammation, damage blood vessels, and disrupt metabolism in ways that can lead to future strokes or even cognitive decline over time.\nIn fact:\n- Obesity and excessive weight gain are the\nleading risk factorsfor developing type 2 diabetes. - People with diabetes are\ntwice as likelyto have a stroke. - Obesity and diabetes both\nincrease the riskof developing dementia. - Stroke survivors with diabetes often face\nslower recovery, poorer outcomes, and higher recurrence rates.\nSo, anything that can reduce stroke recurrence and protect the brain is worth attention.\nWhat This New Study Found Between Semaglutide (Ozempic, Wegovy), Tirzepatide (Mounjaro, Zepbound), and Stroke Risk\nA new cohort study published July 2025 in JAMA Network Open followed over 60,000 adults with both type 2 diabetes and obesity. Researchers compared those taking semaglutide or tirzepatide to others using different diabetes medications.\nHere’s what they discovered:\n- Those on semaglutide or tirzepatide had a:\n- 37% lower risk of developing dementia\n- 19% lower risk of having a stroke\n- 30% lower risk of dying from any cause\nThat’s big news—especially for stroke survivors trying to stay ahead of the curve.\nWhy These Semaglutide or Tirzepatide Might Help Prevent Stroke\nSemaglutide and tirzepatide belong to a class of drugs called GLP-1 receptor agonists. They are widely used among those with type 2 diabetes, and may also be prescribed for individuals managing both type 1 diabetes and obesity.\nOriginally created to help manage blood sugar, these drugs have become famous for supporting weight loss. But researchers are now discovering they might also protect the brain by:\n- Reducing inflammation in the brain\n- Improving blood vessel function\n- Lowering oxidative stress\n- Possibly slowing down the brain changes seen in Alzheimer’s disease\nIn animal studies, these medications have been shown to protect neurons, the cells responsible for memory and movement. That could explain the lower dementia risk seen in humans.\nWhat It Means for Stroke Survivors\nIf you’re a stroke survivor with diabetes or obesity, this research might give you a new reason to talk to your doctor. These medications may offer:\n- Protection against future strokes\n- Better brain health over time\n- A longer, healthier life\nAnd the benefits seem to be strongest in:\n- People over 60\n- Women\n- Those with a BMI between 30–40\nThese are all groups that face a higher baseline risk of dementia and stroke recurrence.\nWhat About Parkinson’s or Brain Bleeds?\nInterestingly, the study did not find a lower risk of Parkinson’s disease or brain hemorrhages (a type of stroke caused by bleeding). So while the protective effects may be strong for some brain conditions, they’re not universal.\nAre These Medications Right for You?\nBefore making any changes to your treatment plan, consider these key points:\n- They’re not for everyone. If you don’t have diabetes or aren’t overweight, these medications aren’t usually prescribed.\n- Adverse side effects are possible. Some people experience nausea, stomach upset, or more serious complications.\n- Cost and access vary. Insurance coverage and availability may affect your options.\nBut if you’re a stroke survivor managing type 2 diabetes or obesity, it’s worth having a conversation with your doctor about the potential long-term benefits.\nLooking Ahead: Takeaway for Stroke Survivors\nWe’re still learning just how far these benefits go. More research is underway, including clinical trials looking at semaglutide’s role in preventing Alzheimer’s disease.\nBut for now, this study suggests something hopeful: medications originally designed for blood sugar and weight may be helping the brain—and reducing the chances of another stroke.\nIf you’ve had a stroke and are managing diabetes or obesity, you may be able to lower your risk of future strokes and dementia with the help of newer medications like semaglutide or tirzepatide.\nTalk to your doctor. Ask questions. And keep building a care plan that supports your recovery—and your future.\nSources: Lin, H.-T., Tsai, Y.-F., Liao, P.-L., et al. “Neurodegeneration and Stroke After Semaglutide and Tirzepatide in Patients With Diabetes and Obesity.” JAMA Network Open. July 15, 2025.",
  "highlightText": "",
  "highlightTitle": "",
  "highlightThreadTitle": "",
  "language": "english",
  "sentiment": "positive",
  "categories": [
    "Health",
    "Science and Technology",
    "Human Interest"
  ],
  "topics": [
    "Health->medical condition",
    "Health->health treatment and procedure",
    "Health->health care approach",
    "Science and Technology->medical research",
    "Science and Technology->biomedical science",
    "Science and Technology->psychology"
  ],
  "ai_allow": true,
  "has_canonical": false,
  "breaking": null,
  "webz_reporter": false,
  "external_links": [
    "https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2836412",
    "https://www.ahajournals.org/doi/10.1161/STROKEAHA.106.481390",
    "https://www.mdpi.com/1422-0067/25/3/1882",
    "https://pmc.ncbi.nlm.nih.gov/articles/PMC6812410/",
    "https://pubmed.ncbi.nlm.nih.gov/39745353/",
    "https://pmc.ncbi.nlm.nih.gov/articles/PMC9408882/",
    "https://www.ncbi.nlm.nih.gov/books/NBK551568/",
    "https://www.e-jcpp.org/journal/view.php?number=105",
    "https://e-jcpp.org/journal/view.php?number=105",
    "https://www.pmc.ncbi.nlm.nih.gov/articles/PMC9408882/",
    "https://ncbi.nlm.nih.gov/books/NBK551568/",
    "https://www.jamanetwork.com/journals/jamanetworkopen/fullarticle/2836412",
    "https://pmc.ncbi.nlm.nih.gov/articles/PMC9408882",
    "https://ahajournals.org/doi/10.1161/STROKEAHA.106.481390",
    "https://www.e-jcpp.org/journal/view.php",
    "https://www.ncbi.nlm.nih.gov/books/NBK551568",
    "https://mdpi.com/1422-0067/25/3/1882",
    "https://pmc.ncbi.nlm.nih.gov/articles/PMC6812410",
    "https://pubmed.ncbi.nlm.nih.gov/39745353",
    "https://www.pmc.ncbi.nlm.nih.gov/articles/PMC6812410/",
    "https://www.pubmed.ncbi.nlm.nih.gov/39745353/"
  ],
  "external_images": [],
  "internal_images": [],
  "entities": {
    "persons": [],
    "locations": [],
    "organizations": []
  },
  "syndication": {
    "syndicated": false,
    "syndicate_id": null,
    "first_syndicated": false
  },
  "trust": {
    "categories": [],
    "top_news": [],
    "bias": null,
    "source": {
      "type": null,
      "city": null,
      "state": null,
      "country": null,
      "domain_type": null,
      "agency": null,
      "organization_name": null
    }
  },
  "rating": null,
  "crawled": "2025-07-24T07:41:45.942+03:00",
  "updated": "2025-07-24T07:48:15.000+03:00"
}